Stock Alert: Checkpoint Therapeutics CKPT Up 45%

Shares of Checkpoint Therapeutics, Inc. (CKPT) are currently gaining nearly 45% on Friday morning despite no stock-specific news to drive the shares. Most of the US stocks are trading higher today as investors are optimistic going forward driven by the promising study results of COVID-19 vaccine.

CKPT is currently trading at $2.42, up $0.75 or 44.91%, on the Nasdaq.

Checkpoint Therapeutics is an immuno-oncology biopharmaceutical company, which focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in Phase I clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and Cosibelimab, a programmed death ligand-1, which is in Phase I clinical trial in patients with selected recurrent or metastatic cancers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT